Clinical Trials Directory

Trials / Sponsors / SK Bioscience Co., Ltd.

SK Bioscience Co., Ltd.

Industry · 12 registered clinical trials — 3 currently recruiting.

StatusTrialPhaseStarted
Not Yet RecruitingSkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years
Varicella (Chickenpox)
Phase 32026-06-05
RecruitingA Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protect
Healthy Participants, Sarbecovirus
Phase 1 / Phase 22026-01-28
RecruitingA Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonuc
Japanese Encephalitis Virus Disease
Phase 1 / Phase 22025-02-24
WithdrawnA Blood Collection Study to Assess the Immunogenicity of Nationally Authorized Homologous COVID-19 Booster Vac
COVID-19
—2023-02-01
CompletedImmunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanopa
COVID-19
Phase 32022-12-09
CompletedImmunogenicity and Safety Study of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine (GBP510) Adjuvanted With AS0
Covid19
Phase 32021-08-30
UnknownSafety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With or Without AS03 (C
COVID-19 (Healthy Volunteers)
Phase 1 / Phase 22021-02-03
CompletedSafety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide
COVID-19 (Healthy Volunteers)
Phase 1 / Phase 22021-01-20
CompletedSafety and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults (COVID-19)
COVID-19 (Healthy Volunteers)
Phase 12020-12-17
CompletedImmunogenicity and Safety Study of NBP615 in Healthy Female
Cervical Cancer
Phase 1 / Phase 22018-12-22
CompletedImmunogenicity and Safety of NBP607-QIV Compared to Agrippal in Children Aged 6 to 35 Months
Influenza
Phase 32018-10-25
CompletedImmunogenicity and Safety of NBP608 Compared to Varivax in Healthy Children 12 Months to 12 Years of Age
Varicella
Phase 32016-07-14